On June 4, 2025, aTyr Pharma (ATYR, Financial) received a reaffirmation from HC Wainwright & Co., as analyst Joseph Pantginis reiterated a 'Buy' rating on the stock. The price target remains steady at $35.00, unchanged from the prior assessment.
According to the latest report, there is no percentage change in the price target for aTyr Pharma (ATYR, Financial), as it holds at $35.00 USD. The consistency in the target price suggests continued confidence in the stock's potential growth.
Investors following aTyr Pharma (ATYR, Financial) may find reassurance in the maintained 'Buy' rating and stable price target, indicating positive sentiment and outlook from HC Wainwright & Co. analyst Joseph Pantginis.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for aTyr Pharma Inc (ATYR, Financial) is $24.60 with a high estimate of $35.00 and a low estimate of $16.00. The average target implies an upside of 358.53% from the current price of $5.37. More detailed estimate data can be found on the aTyr Pharma Inc (ATYR) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, aTyr Pharma Inc's (ATYR, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
